Marker Therapeutics, Inc.
MRKRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Marker Therapeutics, Inc. focuses on Biotechnology services and products. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor. With a market capitalization of $21.2M, it sits in micro-cap territory. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Market Cap
$21.2M
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
-1.68
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.76
ROE
-77.0%
ROA
-43.6%
Cash
$14.9M
Total Debt
$0
Free CF
-$5.2M
52W Change
-19.6%
Annual Financials
Cash vs Debt
Where MRKR stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, MRKR finished 7.33% above its 150-day moving average ($1.50) and 17.52% above its 200-day moving average ($1.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRKR overbought or oversold?
At the July 9, 2026 close, MRKR's RSI(14) was 71.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Marker Therapeutics, Inc. reports $14.9M in cash and $0 in total debt. Free cash flow is running at -$5.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -77.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Marker Therapeutics, Inc.'s trajectory.